Hualan Biological Bacterin (301207) Fundamentals 2026 — P/E 52.9x, Revenue Analysis | SniperIQ
Hualan Biological Bacterin (301207) is a CN-listed Healthcare company in Biotechnology with a market capitalization of ¥10.0B, trading at ¥16.80 on the SHZ. This SniperIQ fundamentals page covers Hualan Biological Bacterin's valuation (P/E 52.9x, P/B 1.7x), profitability (net margin 15.6%), revenue (¥1.2B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Hualan Biological Bacterin's market cap?
Hualan Biological Bacterin (301207) has a market capitalization of approximately ¥10.0B, trading at ¥16.80 on the SHZ. Market cap moves with the live share price.
What is Hualan Biological Bacterin's P/E ratio?
Hualan Biological Bacterin's trailing twelve-month P/E ratio is 52.9x, with a price-to-book (P/B) of 1.7x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Hualan Biological Bacterin?
Hualan Biological Bacterin runs a net profit margin of 15.6%, a gross margin of 75.6%, and an operating margin of 9.2%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Hualan Biological Bacterin generate?
Hualan Biological Bacterin reported revenue of ¥1.2B for fiscal year 2025, with net income of ¥183M and earnings per share (EPS) of 0.31. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Hualan Biological Bacterin pay a dividend?
Hualan Biological Bacterin offers a trailing dividend yield of about 8.3%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Hualan Biological Bacterin financially healthy?
Hualan Biological Bacterin carries a debt-to-equity ratio of 0.00x and a current ratio of 4.15x, with a market beta of 0.63. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Hualan Biological Bacterin a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Hualan Biological Bacterin (301207) the key facts are: market cap ¥10.0B, P/E 52.9x, revenue ¥1.2B, 52-week range 15.43-27.88. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Hualan Biological Bacterin's full fundamentals live
Get Hualan Biological Bacterin's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.